- FDA's acting director of cell and gene therapies to leave positionVijay Kumar is leaving his role as acting director of CBER's Office of Therapeutic Products and will soon consider options both inside and outside the FDA, he told Endpoints News on Tuesday. Kuma…Endpoints · 26d ago↗ source
- Sarepta's FDA decision date; Flare gets Anna Protopapas as CEOPlus news about Deerfield, InflaRx, Praxis, Nuvectis, Pyxis Oncology, Vistagen, Arcutis Biotherapeutics and Nxera. 🔎 FDA to decide on future of Sarepta exon-skipping drugs by end of February: Th…Endpoints · 26d ago↗ source
- STAT+: All of Us tests a new approach to collect real-world data for researchThe NIH All of Us Research Program has secured thousands of electronic medical records through an innovative use of patient data-sharing networks